What is Orsiro stent?
The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting coronary stent (DES) system. Orsiro is the first ultrathin, bioresorbable polymer-coated DES to outperform the current clinical standard Abbott Xience DES. The U.S. FDA cleared the stent in February 2019.
What drug is on Orsiro?
The Orsiro stent (Biotronik) is comprised of three elements: the metallic stent structure, the polymer, and the antiproliferative drug. The drug is a well-proven antiproliferative agent, sirolimus, which has been used effectively and safely in many drug-eluting stents over several different generations.
Is Orsiro a drug-eluting stent?
The Orsiro device is a hybrid drug-eluting stent that represents a new strategy in the treatment of coronary artery stenosis.
Which stent is best for angioplasty?
A drug-eluting stent is the most common type of stent used to treat a blockage of the heart arteries. Many people with heart problems have been successfully treated with drug-eluting stents, preventing the need for more-invasive procedures, such as coronary artery bypass surgery.
Is Orsiro stent good?
The BIOFLOW V study, which was presented 2 years ago at the European Society of Cardiology Congress, garnered significant attention when the 12-month data showed the Orsiro stent was superior to Xience, largely considered the best-in-class, for reducing the risk of target lesion failure at 12 months.
What is a monorail stent?
Promus Element Plus Monorail everolimus-eluting coronary stent system is a medical device used to treat patients who have coronary artery disease. The stent is placed in a coronary artery to widen and keep the artery open.
What are the contraindications for the use of Orsiro and Orsiro mission?
Orsiro and Orsiro Mission are contraindicated for use in patients with a known hypersensitivity or allergy to the stent and/or stent coating materials such as amorphous silicon carbide, PLLA polymer, L-605 cobalt chromium alloy (including the major elements cobalt, chromium, tungsten and nickel), sirolimus or its derivatives.
What is the Orsiro stent system?
Designed for challenging cases, the Orsiro stent system provides better push and easier cross with a lower crossing profile. Indicated for discrete de novo stenotic lesions and in-stent restenotic lesions.*
How many patients have enrolled in Orsiro clinical programs?
Orsiro has an extensive clinical program with more than 55,000 patients enrolled 4. Orsiro Mission, BIOTRONIK’s next generation drug-eluting stent has received FDA approval Everything you need to know about our latest generation DES: 1.
What is the difference between Xience and Orsiro?
ф vs. Xience, based on 36-m frequentist analysis. Orsiro shows numerically equal or lower Stent Thrombosis (ST) in complex patients in comparison to Xience. ‡ Driven by peri-procedural MI events (<48 hours). In-hospital rate may include events > 48 hours.